iCASP9-ΔCD19 T-lymphocytes

iCASP9-ΔCD19 T-lymphocytes are genetically modified T cells engineered to express two main components: **inducible caspase 9 (iCasp9)**, a suicide gene, and **truncated CD19 (ΔCD19)**, a cell surface marker used for positive selection and tracking of modified cells. This approach is primarily designed as a "fail-safe" or *safety switch* for adoptive T-cell therapies, including CAR-T and donor lymphocyte infusions. Upon administration of a specific small-molecule dimerizer (chemical inducer of dimerization, CID, such as AP1903 or AP20187), iCasp9 is activated, leading to rapid apoptosis of the engineered T cells. The ΔCD19 component allows for immunomagnetic selection of the modified cells. The main purpose is to increase patient safety by enabling selective depletion of engineered T cells in cases of severe adverse events such as graft-versus-host disease (GVHD) or unwanted tissue toxicity. iCASP9-ΔCD19 T-lymphocytes have been developed by academic research collaborations and have been investigated in clinical settings for adoptive immunotherapy, mainly in the context of hematopoietic stem cell transplantation and cellular immunotherapy for malignancies[1][2][3][4][5].

Other names

iCasp9-transduced ΔCD19 T cellsiCasp9-modified T cells with truncated CD19iCasp-9-modified T cells with truncated CD19iCasp 9-modified T cells with truncated CD19inducible caspase 9 and ΔCD19 T-lymphocytes